Effects of chronic doxycycline on the development of LID
L-DOPA induced the appearance of dyskinesia in the parkinsonian rats
(6-OHDA+chronic-vehicle+L-DOPA; Fig. 4-A). Co-administration of
doxycycline with L-DOPA (6-OHDA+chronic-doxycycline+L-DOPA decreased the
AIMs measured at days 1, 7, and 14 of the combined treatment
(p<0.0001; Fig. 4-A). Post hoc analyses revealed a significant
reduction of the total AIMs (Fig. 4-A) and the different AIMs types
(Supplementary Figs. 2-D, -E and -F; p<0.05,
6-OHDA+chronic-vehicle+L-DOPA vs. 6-OHDA+chronic-doxycycline+L-DOPA).
AIMs were not observed in the control group or the 6-OHDA-lesioned rats
that were treated with vehicle or doxycycline only (data not shown).
The lesioned animals showed a decrease in the distance traveled, as
evaluated by the open-field test (6-OHDA+chronic-vehicle+vehicle;
Supplementary Table 1), demonstrating compromised motor ability. L-DOPA
treatment increased the distance traveled (6-OHDA+chronic-vehicle+L-DOPA
Supplementary Table 1), and the co-administration of L-DOPA+doxycycline
did not affect the improvement in locomotor activity
(6-OHDA+chronic-doxycycline+L-DOPA p<0.05; Supplementary Table
1).